The business and patient case for drug delivery device innovation in biosimilar products
Currently, almost a fifth of the biologics market, worth $211 billion dollars, is exposed to biosimilar competition. Furthermore, 64% of the market, or $135 billion, comprises molecules with the potential for biosimilar development. Half of these molecules already have biosimilars in the pipeline.
As manufacturers seize this opportunity, they will also need to assess how they can stand out in what will become an increasingly crowded market. With ease-of-use being a high priority for patients, and in light of the growing trend towards patient self-administration, there is an opening for biosimilar manufacturers to innovate in the area of drug delivery.
Darren Mansell, Regulatory Affairs Manager, Owen Mumford delves into the details with Manufacturing Chemist.